Summary
This report offers a concise overview of the VZV Conference, highlighting recent developments in the field and speculating on areas of greatest opportunity and need for future work. The goal of eradicating VZV disease will be facilitated by a multifaceted research agenda directed at a fuller comprehension of how the virus replicates, spreads and persists, and how it eludes host immune responses.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brunell PA, Ren LC, Cohen JI, Straus SE (1999) Viral gene expression in rat trigeminal ganglia following neonatal infection with varicella-zoster virus. J Med Virol 58: 286–290
Culbertson WW, Blumenkranz MS, Pepose JS, Stewart JA, Curtin VT (1986) Varicella zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 93: 559–569
Garnett GP, Ferguson NM (1996) Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol 6: 151–161
Gilden DH, Murray RS, Wellish M, Kleinschmidt-deMasters BK, Vafai A (1988) Chronic progressive varicella-zoster virus encephalitis in an AIDS patient. Neurology 38: 1150–1153
Hope-Simpson RE (1975) Postherpetic neuralgia. J R Coll Gen Pract 25: 571–575
Lungu O, Annunziato PW, Gershon A, Staugaitis SM, Josefson D, LaRussa P, Silverstein SJ (1995) Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci USA 92: 10980–10984
Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ (1998) Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc Natl Acad Sci USA 95: 7080–7085
Kennedy PG, Grinfeld E, Gow JW (1998) Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia. Proc Natl Acad Sci USA 95: 4658–4662
Krause PR, Klinman DM (2000) Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med 6: 451–454
Krause PR, Straus SE (1999) Herpesvirus vaccines. Development, controversies, and applications. Infect Dis Clin North Am 13: 61–81
LaRussa P, Steinberg S, Arvin A, Dwyer D, Burgess M, Menegus M, Rekrut K, Yamanishi K, Gershon A (1998) Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis 178 [Suppl 1]: S64–S66
Levin MJ, Barber D, Goldblatt E, Jones M, laFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR (1998) Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 178 [Suppl] S109–S112
Moffat JF, Zerboni L, Sommer MH, Heineman TC, Cohen JI, Kaneshima H, Arvin AM (1998) The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skill in the SCID-hu mouse. Proc Natl Acad Sci USA 95: 11969–11974
Myers MG, Stanberry LR, Edmond BJ (1985) Varicella-zoster virus infection of strain 2 guinea pigs. J Infect Dis 151: 106–113
Sadzot-Delvaux C, Debrus S, Nikkels A, Piette J, Rentier B (1995) Varicella-zoster virus latency in the adult rat is a useful model for human latent infection. Neurology 45 [Supp l8]: S18–S20
Silverstein S, Straus SE (2000) The pathogenesis of latency and reactivation: the ins and outs of VZV. In: Arvin AM, Gershon AA (eds) Varicella-zoster: basic virology and clinical management. Cambridge University Press, Cambridge
Soike KF (1992) Simian varicella virus infection in African and Asian monkeys. The potential for development of antivirals for animal diseases. Ann NY Acad Sci 653: 323–333
Stemmer SM, Kinsman K, Tellschow S, Jones RB (1993) Fatal noncutaneous visceral infection with varicella-zoster virus in a patient with lymphoma after autologous bone marrow transplantation. Clin Infect Dis 16: 497–499
Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A (1975) Development of a live attenuated varicella vaccine. Biken J 18: 25–33
Takahashi M, Otsuka T, Okuna Y, Asano Y, Yazaki T (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 1288–1290
Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM (1992) Subclinical varicellazoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165: 119–126
Yoshida M, Tamura T, Hiruma M (1999) Analysis of strain variation of R1 repeated structure in varicella-zoster virus DNA by polymerase chain reaction. J Med Virol 58: 76–78
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Wien
About this paper
Cite this paper
Straus, S.E. (2001). Varicella-zoster virus immunity and prevention: a conference perspective. In: Gershon, A.A., Arvin, A.M., Calisher, C.H. (eds) Immunity to and Prevention of Herpes Zoster. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6259-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6259-0_18
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83555-5
Online ISBN: 978-3-7091-6259-0
eBook Packages: Springer Book Archive